MRKR Marker Therapeutics, Inc.
Healthcare$1.45+3.57%ClosedMarket Cap: $15.7M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
1.96
P/S
7.22
EV/EBITDA
-0.02
DCF Value
$1,049,513.29
FCF Yield
-52.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
-99.5%
Operating Margin
-590.0%
Net Margin
-520.3%
ROE
-0.0%
ROA
-62.5%
ROIC
-89.4%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | NaN% | $-4.1M | $-3.2M | $— | — |
| Q4 null | $0.00 | NaN% | $-1.9M | $-1.7M | $— | — |
| FY null | $0.00 | NaN% | $-12.9M | $-12.2M | $— | — |
| Q3 null | $1.2M | 100.0% | $-2.1M | $-2.0M | $— | — |
| Q2 null | $861.2K | -385.0% | $-4.3M | $-4.0M | $— | — |
| Q1 null | $349.1K | -798.1% | $-4.6M | $-4.4M | $— | — |
| Q4 null | $2.3M | -125.9% | $-3.9M | $-3.8M | $— | — |
| FY null | $6.6M | -104.3% | $-11.1M | $-10.7M | $— | — |
| Q3 null | $1.9M | -80.2% | $-2.4M | $-2.3M | $— | — |
| Q2 null | $1.2M | -99.7% | $-2.3M | $-2.2M | $— | — |
| Q1 null | $1.2M | -107.0% | $-2.5M | $-2.4M | $— | — |
| Q4 2023 | $1.1M | -147.7% | $-2.9M | $-2.8M | $-0.31 | — |